Inhibitor Therapeutics Valuation
| INTI Stock | USD 0.04 0.00 0.00% |
Inhibitor Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Inhibitor Therapeutics from evaluating the firm fundamentals such as Current Valuation of 26.98 M, number of shares shorted of 19.88 K, and Return On Asset of -2.11 as well as inspecting its technical indicators and probability of bankruptcy. . In general, most investors encourage purchasing undervalued assets and trading away overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Overvalued
Today
Please note that Inhibitor Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Inhibitor Therapeutics is based on 3 months time horizon. Increasing Inhibitor Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Inhibitor otc stock is determined by what a typical buyer is willing to pay for full or partial control of Inhibitor Therapeutics. Since Inhibitor Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Inhibitor OTC Stock. However, Inhibitor Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.045 | Real 0.041 | Hype 0.05 | Naive 0.0465 |
The intrinsic value of Inhibitor Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Inhibitor Therapeutics' stock price.
Estimating the potential upside or downside of Inhibitor Therapeutics helps investors to forecast how Inhibitor otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inhibitor Therapeutics more accurately as focusing exclusively on Inhibitor Therapeutics' fundamentals will not take into account other important factors: Inhibitor Therapeutics Total Value Analysis
Inhibitor Therapeutics is currently anticipated to have valuation of 26.98 M with market capitalization of 22.99 M, debt of 331 K, and cash on hands of 24.95 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Inhibitor Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
26.98 M | 22.99 M | 331 K | 24.95 K |
Inhibitor Therapeutics Asset Utilization
One of the ways to look at asset utilization of Inhibitor is to check how much profit was generated for every dollar of assets it reports. Inhibitor Therapeutics retains a negative application of resources of -2.11 (percent), losing $0.0211 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Inhibitor Therapeutics shows how discouraging it operates for each dollar spent on its resources.Inhibitor Therapeutics Ownership Allocation
Inhibitor Therapeutics has a total of 376.86 Million outstanding shares. Inhibitor Therapeutics retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 79.33 (percent) of Inhibitor Therapeutics outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Inhibitor Therapeutics Profitability Analysis
Net Loss for the year was (298.63 K) with profit before overhead, payroll, taxes, and interest of 0.About Inhibitor Therapeutics Valuation
An absolute valuation paradigm, as applied to Inhibitor OTC Stock, attempts to find the value of Inhibitor Therapeutics based on its fundamental and basic technical indicators. By analyzing Inhibitor Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Inhibitor Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inhibitor Therapeutics. We calculate exposure to Inhibitor Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Inhibitor Therapeutics's related companies.Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
8 Steps to conduct Inhibitor Therapeutics' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Inhibitor Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Inhibitor Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Inhibitor Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Inhibitor Therapeutics' revenue streams: Identify Inhibitor Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Inhibitor Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Inhibitor Therapeutics' growth potential: Evaluate Inhibitor Therapeutics' management, business model, and growth potential.
- Determine Inhibitor Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Inhibitor Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Inhibitor Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 376.9 M | |
| Retained Earnings | -57.7 M |
Complementary Tools for Inhibitor OTC Stock analysis
When running Inhibitor Therapeutics' price analysis, check to measure Inhibitor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibitor Therapeutics is operating at the current time. Most of Inhibitor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibitor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibitor Therapeutics' price. Additionally, you may evaluate how the addition of Inhibitor Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |